预测儿科狼性炎中mycophenolic acid暴露:在三个临床情景中进行的现实研究
Baojing Liu1,2, Lizhi Chen3, Yuqi Wang1
1Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Rheumatology (Oxford, England)
|February 17, 2026
概括
机器学习模型可以预测儿科狼性炎中菌酸的暴露,从而优化治疗. 这一框架通过个性化剂量策略来提高精准医学,以获得更好的患者结果.
科学领域:
- 药理动力学和药理动力学
- 机器学习在医学中的应用
- 儿科脏病学 儿科脏病学
背景情况:
- 儿童发病的系统性红斑狼 (cSLE) 与狼性炎 (LN) 构成了治疗挑战.
- 在儿科LN患者中,mycophenolic acid (MPA) 的药理动力学是复杂的.
- 对MPA的治疗药物监测 (TDM) 有局限性.
研究的目的:
- 开发机器学习 (ML) 模型来预测度-时间曲线 (MPA-AUC) 下的MPA面积.
- 评估治疗窗口的模型,准确的AUC估计和剂量调整后的暴露预测.
- 建立一个个性化的MPA剂量框架,用于儿科LN.
主要方法:
- 收集了来自154名儿科LN患者的数据,包括常规治疗和剂量调整队列.
- 采用了ML算法,包括XGBoost,LightGBM和随机森林 (RF).
- 利用Shapley添加式解释 (SHAP) 来实现模型的解释性,并开发了一个基于网络的临床决策工具.
主要成果:
- 轻GBM模型在预测治疗窗口的实现方面表现出色 (F1=0.65).
- 使用临床数据和度,RF模型在精确的AUC估计 (R2=0.84) 中取得了高准确性.
- 射频模型证明了剂量调整后暴露的预测能力 (R2=0.51).
- SHAP分析确定了剂量,体重,功能和度时间点作为关键预测因素.
结论:
- 该研究提出了第一个基于ML的框架,用于在儿科LN中个性化MPA剂量.
- 这种方法解决了TDM的局限性,并增强了cSLE患者的精准医学.
- 开发的模型和工具可以支持优化MPA治疗药物监测和临床决策.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
289
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
Pharmacokinetics in Pediatric Patients: Drug Metabolism
258
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
258
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
334
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
334
Pharmacokinetics in Pediatric Patients: Drug Distribution
338
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
338
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
212
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
241
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
241


